INTRODUCTION

During the past two decades, the outbreak of the two betacoronaviruses, severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), have markedly affected humans, with mortality rates of 10% for SARS-CoV and 35% for MERS-CoV (Azhar et al., 2019; Hui & Zumla, 2019). Yet another outbreak, in the form of the coronavirus disease (COVID-19) caused by SARS-CoV-2, which has been believed to be originated in Wuhan, China, at the end of 2019 possibly related to contact with a seafood market has rapidly spread in over 200 countries (Huang et al., 2020). The World Health Organization (WHO) declared the coronavirus outbreak a public health emergency of international concern on January 30 and pandemic on March 11.
As of 16 August 2020, globally a total of 21,294,845 cases of the COVID-19 have been reported, with death rate of around 3.6% (World Health Organization, n.d.).

SARS-CoV-2 shares several common important features with SARS-CoV and MERS-CoV causing epidemics with variable clinical severity featuring lower respiratory tract infections and extra-respiratory manifestations. Unlike MERS-CoV or SARS-CoV infection, 2019-novel coronavirus (2019-nCoV) patients rarely developed intestinal signs and symptoms like diarrhoea (Assiri et al., 2013; Leung et al., 2003). Alike the clinical characteristics of SARS-CoV and MERS-CoV, most patients of COVID-19 presented with fever, dry cough, dyspnoea, sore throat etc. (Guan, Ni et al., 2020; Huang et al., 2020; Wan et al., 2020; Wang, Hu et al., 2020).

Furthermore, the prevalence of hypertension, diabetes mellitus, cardiovascular disease and other comorbidities, as well as complications, also varied between the studies due to the various characteristics of the study populations (Guan, Ni et al., 2020; Huang et al., 2020; Wan et al., 2020; Wang, Hu et al., 2020; Zhang et al., 2020). Although there are many studies regarding the clinical characteristics and comorbidities of COVID-19, but there are limited studies that compared clinical characteristics, comorbidities, treatment options and complications of severe and non-severe patients. The exponential growth of COVID-19 cases is overwhelming healthcare systems of developing countries with limited sources. Currently, there are no proven vaccines or effective treatment against the virus. Therefore, healthcare workers assessment ability to distinguish between mild and severe COVID-19 cases promptly could help save lives and boost healthcare system. The present systematic review and meta-analysis were undertaken to provide a systemic evaluation and detailed estimate to draw the whole clinical picture of COVID-19 in severe and non-severe cases. This assessment will help frontline healthcare workers for emergency preparedness and response to SARS-CoV-2 and its severe outcomes. The main objectives of our meta-analysis are as follows:

- To acquire more accurate conclusions on the clinical features, comorbidities, complications and treatment options among patients with COVID-19.
- To compare clinical features comorbidities, complications and treatment options among severe and non-severe patients.

2 | METHODS

2.1 | Eligibility criteria

The inclusion criteria were as follows: (a) study population: studies with patients diagnosed with COVID-19; (b) comparative studies: studies that compare severe and non-severe cases of COVID-19; and (c) the studies reporting parameters of clinical features, comorbidities, complications and treatment. Non-English studies, letters, case studies, editorials, conference abstracts, vaccination trials studies and articles with abstracts only were excluded. Studies with only paediatric cases were also excluded.

2.2 | Information sources and Searching strategies

We conducted this systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement. The PubMed, Embase, Scopus and Web of Sciences databases were searched for relevant papers. The last search was performed on 20 July 2020. The following search terms were used alone or in combination to find all relevant studies: ‘Novel coronavirus’, ‘Novel coronavirus 2019’, ‘Coronavirus Disease 2019’, ‘2019 nCoV’, ‘COVID-19’, ‘SARS-CoV-2’, ‘novel coronavirus pneumonia’ and ‘severe acute respiratory syndrome coronavirus 2’, characteristics, clinical features, treatment, co-morbidity, complications. The search was limited to articles published in English.

2.3 | Data extraction and outcomes

All duplicate studies were excluded by using by EndNote X 8.0 software. The two investigators who performed the literature search also independently extracted the data from included studies. Disagreements were resolved with a third investigator. Microsoft Excel database was used to record all available information including variables: author, date, age, gender and number of participants in severe and non-severe groups. The prevalence of clinical symptoms such as fever, cough, fatigue, dyspnoea, sore throat, headache, chest pain, comorbidities, complications and treatment options used including antiviral drugs, antibiotics, glucocorticoids, oxygen support, continuous renal replacement therapy (CRRT), non-invasive ventilation (NIV) and invasive mechanical ventilation (IMV) was also recorded.

The primary outcome measure was to compare the prevalence of clinical feature, comorbidities, complications and treatment options in severe cases (ICU cases, patients with elevated TnT level, patients with cardiac injury, cases with SpO2 < 90% and patients with ARDS as the second choice if severe data were not provided) and non-severe (non-ICU cases, patients normal TnT level, patients without cardiac injury, cases with SpO2 ≥ 90% and patients without ARDS as the second choice if non-severe data were not provided).

2.4 | Risk of bias assessment

The potential risk of bias of the included studies was assessed using the MINORS, a methodological index for non-randomized studies. The corresponding scores for comparative studies are 0–6, very low quality; 7–12, low quality; 13–18, moderate quality; and 19–24, high quality (Slim et al., 2003).
2.5 | Statistical analysis of data

All statistical analyses were performed with OpenMeta Analyst version 10.10 (www.cebm.brown.edu/open_meta), a free open-source program and RevMan software version 5.3. Meta-analysis of proportions (and 95% CI) was calculated for the clinical symptoms, comorbidities, complications and treatment options. Binary random effect model was used as clinical data are varied across study population.

The prevalence of clinical symptoms, comorbidities, complications and treatments was illustrated with forest plots. With OR (Odds ratio) as the effect quantity, we used Mantel–Haenszel test with fixed or random effect for further meta-analysis of the clinical symptoms, comorbidities, complications and treatments with statistical differences in severe and non-severe patients. We evaluated heterogeneity across the studies by using the $I^2$ statistic and Cochran’s $Q$ test (Higgins et al., 2003). When $I^2 < 50\%$, the fixed effect model was used, while random effect model was used when $I^2 > 50\%$.

3 | RESULTS

A total of 476 papers were retrieved from the four databases, of which 162 studies were removed as duplicates. Remaining 314 studies were screened by title and abstract and, 293 studies were discarded according to exclusion criteria. After evaluating the 21 full texts, 9 studies were excluded due to presenting data that were irrelevant to our aim. Finally, 12 articles (Guan, Ni et al., 2020; Huang et al., 2020; Wan et al., 2020; Wang, Hu et al., 2020; Zhang et al., 2020), (Guo et al., 2020; Liu et al., 2020; Shi et al., 2020; Tian et al., 2020; Wang, Yang et al., 2020; Wu, Chen et al., 2020; Wu, Li et al., 2020) met the inclusion criteria but some of the required information of severe and non-severe cases was not reported in all of the articles. A flow chart of study selection is shown in (Figure 1).

All included studies were published in 2020 with different sample size that ranged from 41-1,099 patients. The risk of bias of eligible studies is presented in (Table 1). The 12 included studies scored between 18–21, with the mean overall score for all comparative studies being 19.6. According to the MINORS assessment, all studies were considered to have a low risk of bias for selection. The main characteristics of eligible studies are summarized in (Table 2).

3.1 | Demographic characteristics

The overall average age ($\pm SE$) of patients across 12 studies was 50 $\pm$ 2 years (range: 38–64 years). Men (53.8%, 95% CI: 50.3–57.3) were more likely to be infected than women counterparts. The proportion of severe patients in our study was 25.9% (95% CI: 20.8–31.0; Table 3). Chi-square test showed that there was significant difference in gender between severe and non-severe groups ($p < .05$).
3.2 | Clinical features

The result of this meta-analysis showed that the most prevalent clinical symptoms of COVID-19 patients were fever (88.3%, 95% CI: 84.1%–92.5%), cough (62.2%, 95% CI: 52.5%–71.8%), fatigue (39.5%, 95% CI: 28.2%–50.8%), dyspnoea (31.5%, 95% CI: 22.3%–40.7%), sore throat (11.7%, 95% CI: 6.0%–17.4%) and headache (11.1%, 95% CI: 6.1–16.1; Table 3). In the estimate of clinical symptoms, significant heterogeneity (Cochran's $Q$) was observed among the identified studies ($p < .001$) with an $I^2$ varying from 93%–98% (Table 3).

We also compared the prevalence of clinical features between severe patients and non-severe patients. For clinical features, the heterogeneity test results, $I^2$ varied from 50%–86%. Thus, the fixed effect model was adopted for further analysis. The result showed that the incidence of fever, cough, sore throat and headache in severe patients were higher than non-severe group, but without statistical significance [fever: OR $= 1.31$, 95% CI (0.78–2.18), $Z = 1.02$, $p = .31$; cough: OR $= 1.40$, 95% CI (0.96–2.05), $Z = 1.75$, $p = .08$; sore throat: OR $= 1.68$, 95% CI (0.51–5.57), $z = 0.85$, $p = .39$; headache: OR $= 1.38$, 95% CI (0.59–3.21), $z = 0.74$, $p = .45$] (Table 4; Figure 2). Additionally, the incidence of dyspnoea and fatigue was both statistically significant higher in severe patients compared with the non-severe patients [dyspnoea: OR $= 5.68$, 95% CI (3.00–10.76), $Z = 5.33$, $p < .00001$; fatigue: OR $= 1.71$, 95% CI (1.12–2.61), $Z = 2.47$, $p = .01$] (Figure 2).

3.3 | Comorbidities

The most prevalent comorbidities were hypertension (22.6%, 95% CI 16.7%–28.5%), diabetes (11.5%, 95% CI 9.0%–14.1%), cardiovascular disease (10.3%, 95% CI 6.1%–14.5%), followed by cancer (2.5%, 95% CI 1.3%–3.6%), chronic kidney disease (1.8%, 95% CI 0.9%–2.7%) and chronic obstructive pulmonary disease (COPD) (1.6%, 95% CI 0.8%–2.4%). The estimates of comorbidities among identified studies showed significant heterogeneity (Cochran's Q) with an $I^2$ index varied from 52%–92% ($p < .05$; Table 3).

| Study (ref)        | Country | Total patients | Age (years) | Male (%) | Severe (%) |
|--------------------|---------|----------------|-------------|----------|------------|
| Wang, Hu et al. (2020) | China   | 138            | 56          | 54.3     | 26.1       |
| Wang, Yang et al. (2020) | China   | 69             | 42          | 46       | 20.3       |
| Huang et al. (2020)   | China   | 41             | 49          | 73       | 31.7       |
| Wan et al. (2020)     | China   | 135            | 47          | 53.3     | 29.6       |
| (Guan, Ni et al. (2020)) | China   | 1,099         | 47          | 58.1     | 15.7       |
| Zhang et al. (2020)   | China   | 140            | 57          | 50.7     | 41.4       |
| Tian et al. (2020)    | China   | 262            | 47.5        | 48.5     | 17.6       |
| Liu et al. (2020)     | China   | 78             | 38          | 50       | 14.1       |
| Wu, Chen et al. (2020)| China   | 280            | 43.1        | 53.9     | 29.6       |
| Wu, Li et al. (2020)  | China   | 201            | 51          | 63.7     | 41.8       |
| Guo et al. (2020)     | China   | 187            | 58.5        | 48.7     | 27.8       |
| Shi et al. (2020)     | China   | 416            | 64          | 49.3     | 19.7       |
For hypertension, there were 563 cases in severe group (202 hypertension cases, 35.88%) and 1941 cases in non-severe group (311 hypertension cases, 16.26%). The random effect model was adopted as there was heterogeneity among included studies ($I^2 = 57\%$). The pooled effect of hypertension in severe and non-severe cases was $3.01$ (OR $= 3.01$, 95% CI: $2.03$–$4.48$), indicating the incidence of severe risk of the patients with hypertension was 3 times higher than those none (Figure 3). Similarly, the tests result revealed that the incidence of cardiovascular disease in severe group was statistically significant higher than non-severe (Table 4).

For comorbidities like diabetes, cancer, COPD and chronic kidney disease the heterogeneity test results, $I^2$ varied from 0%–49%. So, the fixed effect model was used. Diabetes accounted for 20.25% of severe cases and 7.21% of non-severe cases. Cancer (5.56% of severe cases vs. 1.65% of non-severe cases), COPD (5.03% of severe cases vs. 0.84% of non-severe cases) and chronic kidney disease (4.13% of severe cases vs. 1.14% of non-severe cases) were also more prevalent in severe patients compared with non-severe (Table 4).

Furthermore, the incidence of diabetes, cancer, COPD and chronic kidney disease were statistically significant higher in severe patients.
GIRI et al. compared with the non-severe patients [diabetes: OR = 3.15, 95% CI (2.39–4.15), Z = 8.13, p < .00001; cancer: OR = 3.04, 95% CI (1.81–5.12), Z = 4.19, p < .0001; COPD: OR = 6.26, 95% CI (3.34–11.72), Z = 5.72, p < .00001; chronic kidney disease: OR = 3.31, 95% CI (1.73–6.36), z = 3.60, p = .0003] (Figure 3).

### Complications

Regarding the complications, ARDS (22.2%, 95% CI: 10.6%–33.8%), acute kidney injury (3.6%, 95% CI: 1.4–5.8) and shock (1.3%, 95% CI: 0.1–2.5) were the most prevalent complications (Table 3). The pooled effect of ARDS in severe and non-severe cases was 17.86 (OR = 17.86, 95% CI: 9.21–34.64), indicating the incidence of severe risk of the patients with ARDS was 17.86 times higher than those none. Similarly, in severe and non-severe cases the pooled effect of shock and acute kidney injury were 29.31 and 7.16, respectively (Figure 4).

### Treatment

With regard to the treatment options, antiviral drugs (87.4%, 95% CI: 78.3–96.4), antibiotics (77.5%, 95% CI: 64.2–90.8), oxygen support...
GIRI et al. (67.6%, 95% CI: 52.0–83.1), glucocorticoids (36%, 95% CI: 20.4–51.6), NIV (24.4%, 95% CI: 10.7–38.0), IMV (8.4%, 95% CI: 4.1–12.6) and CRRT (0.9%, 95% CI: 0.0–2.1) were the most prevalent treatments used to treat COVID-19 patients (Table 3).

The frequency of antiviral drugs and oxygen support used in severe cases were higher than the non-severe cases but without statistical significance [antiviral drugs: OR = 0.98, 95% CI (0.44–2.20), Z = 0.04, p = .97; oxygen support: OR = 0.21, 95% CI (0.03–1.55), Z = 1.52, p = .13] (Figure 3). The data also revealed a significant higher incidence of antibiotics, glucocorticoids, IMV, NIV and CRRT use in severe patients compared with the non-severe patients [antibiotics: OR = 6.27, 95% CI (2.80–14.04), Z = 4.47, p < .00001; glucocorticoids: OR = 6.36, 95% CI (3.59–11.27), Z = 6.34, p < .00001; IMV: OR = 80.70, 95% CI (20.31–320.61), z = 6.24, p < .00001; NIV: OR = 102.30, 95% CI (17.83–587.00), z = 5.19, p < .00001; CRRT: OR = 24.79, 95% CI (7.53–81.65), z = 5.28, p < .00001] (Table 4; Figure 5).

DISCUSSION

The continued occurrence of SARS-CoV-2 infection globally is deeply concerning. Despite outbreak prevention and control measures, there is no substantial pandemic change, even after seven months from the onset of SARS-CoV-2 outbreak still cases of this infection are increasing at an alarming rate. The present meta-analysis showed that men were more likely to be infected with COVID-19 than female counterparts. Previous studies also showed male predominance in incidence of MERS-CoV and SARS-CoV infections (Badawi & Ryoo, 2016; Leong et al., 2006). The reason for this might be females are relatively resistant to virus infections as they have stronger innate and adaptive immune responses (Klein & Flanagan, 2016).

The most prevalent symptoms of COVID-19 were fever, cough, fatigue, dyspnea and sore throat. The clinical picture of SARS-CoV-2 is similar to SARS-CoV and MERS-CoV infections (Badawi & Ryoo, 2016; Leong et al., 2006). The reason for this might be females are relatively resistant to virus infections as they have stronger innate and adaptive immune responses (Klein & Flanagan, 2016).
which was prevalent in patients with MERS-CoV or SARS-CoV was rare in case of COVID-19 (Assiri et al., 2013; Fan et al., 2006). Recent study from Singapore and United States of America also revealed that in patients with SARS-CoV-2 infection the main symptoms were fever, cough, dyspnoea and sore throat and so on (Arentz et al., 2020; Young et al., 2020). The incidence of fever, cough, dyspnoea, fatigue, sore throat and headache in severe patients was more common than non-severe group. Previous studies also showed that compared with non-severe patients, these symptoms were more common in severe patients (Guan, Ni et al., 2020; Huang et al., 2020; Wan et al., 2020; Wang, Hu et al., 2020).

Results of our meta-analysis demonstrated that the most prevalent comorbidities were hypertension, diabetes and cardiovascular disease. In addition to these comorbidities, cancer, chronic kidney disease and chronic obstructive pulmonary disease (COPD) were also obvious in some patients. The comorbidities identified in our study are in line with previous studies (Guan, Liang et al., 2020; Zumla et al., 2015). A meta-analysis of 637 MERS-CoV cases by Badawi et al suggested that hypertension, diabetes and cardiac disease were prevalent in most patients (Badawi & Ryoo, 2016). Our findings suggested that in severe patients of COVID-19, the incidence of comorbidities such as hypertension, diabetes and cardiac disease, chronic kidney disease etc., was higher than that in non-severe patients. Hence, severe patients may have adverse clinical outcomes compared with non-severe cases. In line with our findings, a study by Alqahtani et al also demonstrated that chronic conditions such as diabetes, hypertension, cardiac disease and renal disease significantly influenced the severity of MERS-CoV (Alqahtani et al., 2018). Similarly in case of SARS and severe pandemic influenza, comorbidities such as obesity, cardiovascular disease, hypertension, metabolic and dermatologic diseases were strongly associated with the disease severity (Mertz et al., 2013; Moni & Liò, 2014).
regulation of the host’s innate and humoral immune responses by these co-morbid conditions may limit their ability to counteract any new viral infection. Moreover, severe patients of COVID-19 had higher concentrations of GCSF, IP10, MCP1, MIP1A and TNFα suggesting that the cytokine storm was associated with disease severity (Huang et al., 2020). Our finding implies that comorbidities should be taken into account when predicting the prognosis in patients with COVID-19.

With regard to the complication, 22.2% of the patients presented with ARDS, while shock and acute kidney injury were less prevalent. Excessive inflammation reactions with a cytokine storm leading to ARDS were prominently seen in SARS and MERS cases (Kim et al., 2016; Lew et al., 2003). Cytokines including TNFα, IL-1β, IL-2, IL-6, IFNα, IFNβ, IFNγ and MCP-1 released by cytokine storm induce immune cells to produce free radicals which are major causes of ARDS (Tisoncik et al., 2012). Patients with COVID-19 pneumonia who had developed ARDS had significantly higher cytokines contributing to cytokine storm (Wu, Chen et al., 2020).

COVID-19 presents an unprecedented challenge to identify effective drugs for prevention and treatment. Currently, there is not any specific effective antiviral treatment for COVID-19. Variety of therapies that have been used or proposed for the treatment SARS-CoV, MERS-CoV and other viral diseases are also being used for the treatment of COVID-19 patients. The results of our meta-analysis revealed that antiviral treatments were administered to 87.4% of the patients. Up to 5%–10% COVID-19 patients can have severe, potentially lethal course, there have been more than 300 clinical trials going on, and the results are highly anticipated to find an effective antiviral treatment for COVID-19 (Sanders et al., 2020).

Macrolide antibiotics such as erythromycin and azithromycin have anti-bacterial, immunomodulatory effects and anti-inflammatory effects. Although the mechanism of azithromycin against SARS-CoV-2 is unclear at present, an open-label non-randomized clinical trial by Gautret et al. showed that hydroxychloroquine in combination with azithromycin treatment might be an efficient antiviral therapy for COVID-19 (Gautret et al., 2020). Our results demonstrated that antibiotics were used in about 77.5% patients and use of antibiotics was significantly higher in severe patients compared with the non-severe patients. Results of recent studies also showed that antibiotics were predominantly used in COVID-19 patients (Guan, Ni et al., 2020; Huang et al., 2020; Wan et al., 2020; Wang, Hu et al., 2020).

**FIGURE 4** Meta-analysis for the proportion acute respiratory distress syndrome, acute kidney injury and shock in COVID-19 cases. Weights are calculated from binary random-effects model analysis. Values represent proportions of the complications in the COVID-19 patients and 95% CI. Heterogeneity analysis was carried out using Q test, the among studies variation ($I^2$ index). Forest plots depict the comparison of the incidences of these three complications in severe and non-severe patients.
Previous studies have demonstrated that in patients with SARS and MERS corticosteroids did not improve survival, but resulted in high complications and delayed viral clearance (Arabi et al., 2018; Lee et al., 2004). In our study, glucocorticoid was used in about 36% of patients and it was given to more severe cases. Corticosteroids might have been used to tackle a cytokine storm, to prevent acute lung injury and ARDS (Sanders et al., 2020; Tisoncik et al., 2012). However, due to the limitations of the available literature, the use of glucocorticoids is still controversial. Therefore, the routine use of corticosteroids in patients with COVID-19 should be avoided unless indicated for another reason. More studies are needed to elucidate the usefulness of corticosteroids in the treatment of COVID-19.

Our systematic review had limitations. Firstly, most of the data in this study are from retrospective studies and all included studies are from China. Secondly, only few studies are available for inclusion as there are limited studies that compared severe and non-severe patients; the test efficiency is insufficient. It would be better to include randomized controlled trials in near future from different parts of world with larger sample size to get detailed understanding of COVID-19.

5 | CONCLUSION

Based on our results, frontline healthcare professionals such doctors and nurses should be aware that the severe patients might manifest more severe clinical symptoms than the general population. People with pre-existing comorbidities will need to be considered as a high-risk group for COVID-19. Our findings may contribute to a better understanding of patient at risk and can help to improve the assessment and management of severe patients. Furthermore, severity of COVID-19 has exerted immense pressure on healthcare system of developing countries and early identification of patients at risk for severe illness may reduce the burden on healthcare system.
ACKNOWLEDGEMENT
We would like to thank Dr. Guichuan Huang for his assistance in this research.

CONFLICT OF INTEREST
All authors disclose no conflict of interest.

AUTHOR CONTRIBUTIONS
Mohan Giri, Anju Puri: Study design. Mohan Giri, Anju Puri, Ting Wang, Shuliang Guo: Data collection and analysis. In addition, all authors read and approved the final manuscript.

ETHICAL APPROVAL
The study does not require ethical approval because the meta-analysis is based on published research.

DATA AVAILABILITY STATEMENT
The data used to support the findings of this study are available from the corresponding author upon request.

ORCID
Mohan Giri https://orcid.org/0000-0001-8588-5482

REFERENCES
Alqahtani, F. Y., Aleanizy, F. S., El Hadi, A., Mohamed, R., Alanazi, M. S., Mohamed, M., Alrasheed, M. M., Abanmy, N., & Alhawassi, T. (2018). Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: A retrospective study. *Epidemiology and Infection*, 147, 1–5. https://doi.org/10.1017/S0950268818002923

Arabi, Y. M., Mandourah, Y., Al-Hameed, F., Sindhi, A. A., Almekhlafi, G. A., Hussein, M. A., Jose, J., Pinto, R., Al-Omari, A., Kharaba, A., Almotairi, A., Al Khatab, K., Alraddadi, B., Shalhoub, S., Abdulmomen, A., Qushmaq, I., Mady, A., Solaiman, O., Al-Aithan, A. M., ... Fowler, R. A. (2018). Corticosteroid therapy for critically Ill patients with middle east respiratory syndrome. *American Journal of Respiratory and Critical Care Medicine*, 197(6), 757–767. https://doi.org/10.1164/rccm.201706-1172OC

Arentz, M., Yim, E., Klaff, L., Lokhandwala, S., Riedo, F. X., Chong, M., & Lee, M. (2020). Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State. *JAMA*, 323(16), 1612–1614. https://doi.org/10.1001/jama.2020.4326

Assiri, A., Al-Tawfiq, J. A., Al-Rabeelah, A. A., Al-Rabiah, F. A., Al-Hajjar, S., Al-Barrak, A., Flemban, H., Al-Nassir, W. N., Balkhy, H. H., Al-Hakeem, R. F., Mahdoom, H. Q., Zumla, A. I., & Memish, Z. A. (2013). Epidemiological, demographic and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: A descriptive study. *The Lancet Infectious Diseases*, 13(9), 752–761. https://doi.org/10.1016/S1473-3099(13)70204-4

Azhar, E. I., Hui, D. S. C., Memish, Z. A., Drosten, C., & Zumla, A. (2019). The Middle East respiratory syndrome (MERS). *Infectious Disease Clinics of North America*, 32(4), 891–905. https://doi.org/10.1016/j.idc.2019.08.001

Badawi, A., & Ryoo, S. G. (2016). Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): A systematic review and meta-analysis. *International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases*, 49, 129–133. https://doi.org/10.1016/j.ijid.2016.06.015

Fan, C. K., Yieh, K. M., Peng, M. Y., Lin, J. C., Wang, N. C., & Chang, F. Y. (2006). Clinical and laboratory features in the early stage of severe acute respiratory syndrome. *Journal of Microbiology, Immunology and Infection = Wei Mian Yu Gan Ran Za Zhi*, 39(1), 45–53.

Gautret, P., Lagier, J.-C., Parola, P., Hoang, V. T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V. E., Tissot Dupont, H., Honoré, S., Colson, P., Chabrière, E., La Scola, B., Rolain, J.-M., Brouqui, P., & Raoult, D. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. *International Journal of Antimicrobial Agents*, 56(1), 105949. https://doi.org/10.1016/j.ijantimicag.2020.105949

Guan, W.-J., Liang, W.-H., Zhao, Y. I., Li, H.-R., Chen, Z.-S., Li, Y.-M., Liu, X.-Q., Chen, R.-C., Tang, C.-L., Wang, T., Ou, C.-Q., Li, L. I., Chen, P.-Y., Sang, L., Wang, W., Li, J.-F., Li, C.-C., Ou, L.-M., Cheng, B. O., ... He, J.-X. (2020). Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. *The European Respiratory Journal*, 55(5), 2000547. https://doi.org/10.1183/13993003.00547-2020

Guan, W.-J., Ni, Z.-Y., Hu, Y. U., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., Du, B., Li, L.-J., Zeng, G., Yuen, K.-Y., Chen, R.-C., Tang, C.-L., Wang, T., Chen, P.-Y., Xiang, J., ... Zhong, N.-S. (2020). Clinical characteristics of Coronavirus disease 2019 in China. *The New England Journal of Medicine*, 382(18), 1708–1720. https://doi.org/10.1056/NEJMoa200232

Guo, T., Fan, Y., Chen, M., Wu, X., Zhang, L., He, T., Wang, H., Wan, J., Wang, X., & Lu, Z. (2020). Cardiovascular implications of fatal outcomes of patients with Coronavirus disease 2019 (COVID-19). *JAMA Cardiology*, 5(7), 1–8. https://doi.org/10.1001/jamacardio.2020.1017

Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003). Measuring inconsistency in meta-analyses. *BMJ (Clinical Research Ed.)*, 327(7414), 557–560. https://doi.org/10.1136/bmj.327.7414.557

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Li, Z., Wang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., ... Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet (London, England)*, 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5

Hui, D. S. C., & Zumla, A. (2019). Severe acute respiratory syndrome: Historical, epidemiologic and clinical features. *Infectious Disease Clinics of North America*, 33(4), 869–889. https://doi.org/10.1016/j.idc.2019.07.001

Kim, E. S., Choe, P. G., Park, W. B., Oh, H. S., Kim, E. J., Nam, E. Y., Na, S. H., Kim, M., Song, K. H., Bang, J. H., Park, S. W., Kim, H. B., Kim, N. J., & Oh, M. D. (2016). Clinical progression and cytokine profiles of middle east respiratory syndrome Coronavirus infection. *Journal of Korean Medical Science*, 31(11), 1717–1725. https://doi.org/10.3346/jkms.2016.31.11.1717

Klein, S. L., & Flanagan, K. L. (2016). Sex differences in immune responses. *Nature Reviews. Immunology*, 16(10), 626–638. https://doi.org/10.1038/nri.2016.90

Lee, N., Allen Chan, K. C., Hui, D. S., Ng, E. K. O., Wu, A., Chiu, R. K. W., Wong, V. W. S., Chan, P. K. S., Wong, K. T., Wong, E., Cockram, C. S., Tam, J. S., Sung, J. J. Y., & Lo, Y. M. D. (2004). Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. *Journal of Clinical Virology: The Official Journal of the Pan American Society for Clinical Virology*, 30(2), 105–112. https://doi.org/10.1016/j.jcv.2004.02.006

Leong, H.-N., Earnest, A., Lim, H.-H., Chin, C.-F., Tan, C. S. H., Puahindarn, M. E., Tan, A. C. H., Chen, M. I. C., & Leo, Y.-S. (2006). SARS in Singapore–predictors of disease severity. *Annals of the Academy of Medicine, Singapore*, 35(5), 326–331.

Leung, W.K., To, K.-F., Chan, P.K.S., Chan, H. L.Y., Wu, A. K. L., Lee, N., Yuen, K. Y., & Sung, J. J. Y. (2003). Enteric involvement of severe acute respiratory syndrome (SARS) in Hong Kong. *The Lancet*, 361(9356), 932–937.
